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Objective: In a phase II clinical trial in nine obese, insulin-resistant humans, we observed
that treatment with KDT501, a novel isohumulone drug, increased total and high-molecular weight (HMW) adiponectin in plasma. The objective was to determine whether
KDT501 increased adiponectin secretion from subcutaneous white adipose tissue (SC
WAT) and the underlying mechanism(s).
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Methods: Nine obese participants with either prediabetes or with normal glucose
tolerance plus three features of metabolic syndrome were part of the study. SC WAT
biopsies were performed before and after 28 days of KDT501 treatment in a clinical
research setting. In addition, a cold stimulus was used to induce thermogenic gene
expression. Adiponectin secretion was measured, and gene expression of 130 genes
involved in adipose tissue function was determined. The effect of KDT501 on adipocyte
mitochondrial function was analyzed in vitro.
Results: SC WAT explants secreted more total and HMW adiponectin after KDT501
treatment (P < 0.05). After KDT501 treatment, a number of genes involved in thermogenesis and lipolysis were induced by cold (P < 0.05). KDT501 also potentiated
β-adrenergic signaling (P < 0.001) and enhanced mitochondrial function in adipocytes
(P < 0.001).
Conclusion: KDT501 induced adiponectin secretion posttranscriptionally and increased
gene expression of thermogenic and lipolytic genes in response to cold stimulation.
These beneficial effects on SC WAT may be explained by the ability of KDT501 to potentiate β-adrenergic signaling and enhance mitochondrial function in adipocytes.
Clinical Trial Registration: https://www.ClinicalTrials.gov, ID number: NCT02444910.
Keywords: adiponectin, adipocyte secretion, adipose tissue biology, gene expression profiling, metabolic
syndrome, mitochondria

INTRODUCTION
KDT501 is a compound chemically derived from hops that has antidiabetic effects in rodents (1).
More specifically, KDT501 is the potassium salt of the n-(isobutyl) congener of a tetrahydro iso-alpha
acid, also known as isohumulone. We have recently analyzed the effect of 1 month of KDT501 treatment in nine obese, insulin-resistant subjects in an open-label, phase II clinical trial (2). Although
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oral glucose tolerance did not improve significantly, there were
improvements in several secondary outcomes. KDT501 treatment reduced plasma triglyceride levels during a lipid tolerance
test. Total and high-molecular weight (HMW) adiponectin
were higher in plasma after KDT501 treatment (2). Adiponectin
is an anti-inflammatory, insulin-sensitizing adipokine that is
negatively correlated with several aspects of metabolic syndrome
and polycystic ovary syndrome (PCOS) (3) and acts at multiple
tissues to promote metabolic homeostasis [recently reviewed
in Ref. (4)]. Consistent with this, plasma TNFα was reduced by
KDT501 treatment (2).
Adiponectin is specifically expressed by adipocytes, suggesting that KDT501 treatment in this clinical trial affected adipose
tissue to increase plasma adiponectin levels (2). KDT501 has
pleiotropic effects on gene expression in vitro. For instance,
KDT501 promoted adiponectin gene expression in a human
adipocyte primary cell culture model (1). KDT501 also inhibited
inflammatory gene expression in macrophages in vitro (1).
In obesity, adipose tissue secretes TNFα (5, 6), an inflammatory
cytokine that is inversely coordinated with adiponectin expression and insulin sensitivity (7). These observations suggest
that KDT501 treatment reduces some measures of adipose
dysfunction in part by remodeling gene transcription.
In this study, we focused on adipose tissue to identify mechanisms by which KDT501 functions in vivo in these nine obese
human research participants. We evaluated adiponectin secretion
from abdominal subcutaneous white adipose tissue (SC WAT)
explant secretions of the participants before and after treatment
with KDT501 from our phase 2 study (2). We then comprehensively evaluated the subcutaneous adipose tissue transcriptional
response to KDT501. Since KDT501 promotes weight loss in
rodents (1), we hypothesized that KDT501 treatment would
reduce adipose dysfunction that occurs with obesity in humans.
Comprehensive analysis of gene expression could thus provide
insight into the mechanism by which KDT501 increases adiponectin secretion in vivo and affects overall SC WAT function.
The panel of genes in our multiplex assay included genes involved
in the function of adipose tissue and genes involved in adipose
dysfunction such as inflammatory cytokines, immune cell type
markers, and fibrosis genes. Because KDT501 was found to
stimulate thermogenic genes in cultured human adipocytes (1),
we measured these genes before and after a brief cold stimulus. To
gain mechanistic insight into the effect of KDT501 on adipocytes,
we evaluated the effect of KDT501 on adipocyte mitochondrial
bioenergetics and fatty acid oxidation in vitro.

and fasting labs, and 9 of these subjects met inclusion/exclusion
criteria and were enrolled in the study. All nine of these subjects completed the study. The characteristics of these subjects;
inclusion and exclusion criteria; and the Phase II KDT501
drug trial (ClinicalTrials.gov ID number NCT02444910) have
recently been reported (2). In brief, nine obese, non-diabetic,
insulin-resistant subjects were given KDT501 in escalating doses
for 28 days during the summer. The relatively short duration of
treatment and the limited doses of KDT501 was a requirement of
the FDA during this phase 2A study. This short-term treatment
did not cause a change in appetite, weight (pre: 100.8 ± 5.5 kg;
post: 100.3 ± 5.7 kg; P = 0.63), % body fat (pre: 47.5 ± 1.55;
post: 47.6 ± 1.5; P = 0.5), resting energy expenditure (pre:
1,725 ± 79 kcal/day; post: 1,670 ± 106 kcal/day; P = 0.29), or respiratory quotient (pre: 0.86 ± 0.02; post: 0.87 ± 0.02; P = 0.0.86);
all values are mean ± SEM. SC WAT biopsies were performed
before and after 28 days of KDT501 treatment; all posttreatment
biopsies were obtained between 0 and 3 days after the last dose
of KDT501. In addition, a cold stimulus was used to determine
whether KDT501 affected thermogenic gene induction. A sub
cutaneous adipose biopsy was performed on the right side of
the abdomen. An ice pack was applied to the left side of the abdomen for 30 min, and a second biopsy was performed 4 h later
on the cold-stimulated adipose. A portion of the adipose tissue
was analyzed for secretion as described below. The remaining
adipose tissue was immediately frozen in liquid nitrogen and
stored at −80°C.

Adipose Tissue Explant Secretions

We weighed 0.5 g of fat from each SC WAT biopsy, placed
the explant into 2 mL Dulbecco’s modified Eagles’ medium
(DMEM), and incubated for 1 h at 37°C. The adipose explant
was removed, and the DMEM was centrifuged to remove
debris. The experiment thus maintained the SC WAT weight
to volume of DMEM ratio similar to the normalization applied
by Kovacova and colleagues (8). The medium was diluted 1:100
and analyzed with a total and HMW adiponectin ELISA kit
(47-ADPHU-E01; Alpco, Salem, NH, USA) according to the
manufacturer’s instructions.

Gene Expression

RNA was prepared from the subcutaneous adipose tissue using
a Qiagen RNAeasy Lipid Tissue Mini kit (Qiagen, Valencia, CA,
USA). RNA quantity and quality were determined using an
Agilent 2100 Bioanalyzer (Palo Alto, CA, USA). The expression
of 130 genes was analyzed using the Nanostring nCounter multiplex system (gene names and accession numbers are in Table
S1 in Supplementary Material). The data were normalized to the
positive controls and the geometric mean of six housekeeping
genes (Table S1 in Supplementary Material) according to the
manufacturer’s instructions. The background level of the standard negative controls supplied by Nanostring was very low and
not subtracted. We also determined the negative control value of
the individual probes by doing no RNA (water) controls. These
values, which are the average of three controls, were also low (see
Tables S2–S5 in Supplementary Material). The gene expression
of ERp44, ERo1-La, and DsbA-L was determined by real-time

MATERIALS AND METHODS
Human Subjects and Study Design

All subjects gave informed consent, and the protocols were
approved by the Institutional Review Board at the University of
Kentucky. Recruitment for this study was through local advertising and initial phone screening eliminated from consideration
participants who could not participate or who did not meet
inclusion criteria, such as BMI and age. 15 potential subjects
were invited for in-person screening, which included an OGTT
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reverse transcriptase polymerase chain reaction (RT-PCR) as
described (9) and normalized the geometric mean of the same six
genes utilized in the Nanostring assay (Table S1 in Supplementary
Material).

5 mM HEPES; pH 7.4) for 1 h before the addition of vehicle
(33 µM BSA) or 167 µM palmitate in complex with BSA (5:1).
Real-time oxygen consumption was measured immediately after
palmitate addition and following injections of 4 µM oligomycin,
4 µM FCCP, and a combination of 2 µM rotenone and 2 µM
antimycin A. The concentration of oligomycin and FCCP was
increased in fatty acid oxidation rate assays to account for the
presence of BSA.

Cell Culture

Primary brown preadipocytes were isolated from neonatal
wild-type C57BL/6 pups as previously described (10). Briefly,
brown adipose tissue was digested for 30 min at 37°C using
1.5 mg/mL collagenase type I (Worthington) in PBS containing
the following additional components: 62 mM NaCl, 2.5 mM
KCl, 0.65 mM CaCl2, 2.5 mM glucose, 50 mM HEPES, and
2% fatty acid-free BSA. Cells were strained using a 100 µM
filter, plated, and grown to confluence in 20% FBS-DMEM.
Differentiation was initiated by replacing the growth media
with 10% FBS-DMEM supplemented with 172 nM insulin,
1 µM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine
(IBMX), 1 nM triiodothyronine (T3), and 1 µM rosiglitazone.
After 2 days, adipogenesis induction media were replaced with
10% FBS-DMEM containing 172 nM insulin and 1 nM T3 and
refreshed every other day. Five days after the induction of differentiation, differentiated brown adipocytes were replated onto a
96-well Seahorse plate at a density of 5,000 cell/well and allowed
to settle overnight. Cells were treated with vehicle, rosiglitazone, and KDT501 for 16 h before analysis of mitochondrial
respiration parameters on a Seahorse XFe96 extracellular flux
analyzer. 3T3-L1 preadipocytes were cultured and differentiated as previously described (11). Briefly, 3T3-L1 preadipocytes
were maintained in 10% BCS-DMEM. To induce differentiation, cells were replated and allowed to reach confluence. Two
days post-confluence, cells were treated with 172 nM insulin,
1 µM dexamethasone, 0.5 mM IBMX, and 1 µM rosiglitazone
in 10% FBS-DMEM. After 2 days, adipogenesis induction
media were replaced with 10% FBS-DMEM supplemented with
172 nM insulin. Differentiated adipocytes were replated onto
96-well Seahorse plates at 6,000 cells per well and allowed to
settle overnight. Cells were treated with vehicle, rosiglitazone,
or KDT501 for 48 h before the fatty acid oxidation rate was
measured in the Seahorse XFe96.

Statistics

Unless noted, data were analyzed with a two-tailed, paired t-test.
To identify genes that had a differential response to cold stimulus by KDT501 treatment, we calculated the difference in the
response to cold stimulus before and after KDT501 treatment
and then performed a two-sample t-test on this difference.
Statistical significance was set at P < 0.05. Data from in vitro
experiments with cultured adipocytes were analyzed by one-way
analysis of variance (ANOVA).

RESULTS
KDT501 Treatment Stimulates
Adiponectin Secretion

We previously reported that KDT501 treatment increased total
and HMW adiponectin levels in plasma (2). When the SC WAT
biopsies were performed in that study, a portion was immediately frozen for mRNA analyses and another portion (0.5 g)
was placed in DMEM for 1 h so that we could analyze secreted
proteins. We evaluated total and HMW adiponectin secretion
from SC WAT explants before and after KDT501 treatment.
KDT501 treatment induced a 1.5-fold increase in the secretion of
total adiponectin (Figure 1A; P < 0.05) and HMW adiponectin
(Figure 1B; P < 0.05) from the adipose tissue explants. However,
adiponectin gene expression was unchanged by KDT501 treatment (Figure 1C), indicating that the increase in secretion occurs
by a posttranscriptional mechanism. These results indicate that
increased secretion of adiponectin from subcutaneous adipose
tissue contributes to the increase in plasma adiponectin of these
research participants after KDT501 treatment (2). Linear regression modeling was used to assess associations between changes
in adiponectin secretion by KDT501 treatment and gender, age,
and BMI. However, results were not statistically significant and
therefore are not presented.

Mitochondrial Bioenergetics and Fatty
Acid Oxidation Rate Assays

Analyses of mitochondrial respiration parameters and fatty acid
oxidation rates were performed in an XFe6 instrument following
the manufacturer’s instructions (Seahorse Bioscience). Briefly,
primary brown adipocytes were switched to substrate-free
DMEM supplemented with 10 mM glucose, 10 mM pyruvate,
1× Glutamax, 10 mM HEPES pH 7.4, and a Mitostress test was
performed. The oxygen consumption rate was measured in real
time to document basal respiration and four sequential injections
were then performed: (1) 100 nM norepinephrine (NE); (2) 2 µM
oligomycin; (3) 1 µM carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP); and (4) a combination of 2 µM rote
none and 2 µM antimycin A. To measure the fatty acid oxidation
rate, 3T3-L1 adipocytes were switched to assay media (Krebs–
Henseleit Buffer, 2.5 mM final glucose, 0.5 mM carnitine, and
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Effect of KDT501 on Adipose
Tissue Gene Expression

To identify potential mechanisms of action of KDT501, we
analyzed gene expression in abdominal SC WAT with the
Nanostring nCounter multiplex system. The gene panel comprised cytokines, chemotactic factors, immune cell markers,
fibrosis markers, angiogenesis markers, genes involved in lipid
handling, adipogenesis makers, genes involved in thermogenesis, and markers of brown and beige adipose (Table S1 in
Supplementary Material). Table 1 shows that KDT501 treatment
caused significant changes in only four adipose genes; four
additional genes with non-significant trends (0.05 < P < 0.1) for
3
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TABLE 1 | Gene expression changed by KDT501 treatment.
Genea

Pre KDT501

Post KDT501

Fold change

P

Post/pre
TNFRSF12A
ACACA
MPZL2
DGAT2
LPL
TMEM26
TIMP1
DIO2

12 ± 2
229 ± 45
52 ± 8
12,059 ± 2,187
17,455 ± 2,836
16 ± 2
1,382 ± 89
27 ± 6

16 ± 2
196 ± 35
73 ± 12
10,482 ± 1,941
15,793 ± 2,584
13 ± 2
1,600 ± 158
38 ± 9

1.345
0.857
1.407
0.869
0.905
0.856
1.157
1.392

0.037
0.038
0.041
0.043
0.068
0.072
0.075
0.095

SCWAT was isolated before and after KDT501 treatment, and gene expression
determined with the Nanostring nCounter system as described in the Section
“Materials and Methods.”
The data are presented as means (nCounter Counts) ± SEM (n = 9; two-tailed, paired
Student’s t-test).
a

change are also indicated in Table 1. KDT501 treatment reduced
the mRNA expression of ACACA (Table 1; 0.86-fold; P = 0.038),
which regulates fatty acid synthesis, and DGAT, which regulates
triglyceride formation (Table 1; 0.87-fold; P = 0.043). The mRNA
expression of LPL, which regulates lipid and lipoprotein uptake,
tended to be reduced (Table 1; P = 0.068). Together, these results
suggest a slight reduction in genes controlling adipose tissue
lipid synthesis, uptake, and storage. MPZL2, which is a brown
adipose marker (12), was induced 1.4-fold (Table 1; P = 0.041),
and there was a trend for an increase in DIO2, which is involved
in energy metabolism through the conversion of T4 into T3.
However, UCP1 (P = 0.7) and PGC1α (P = 0.37), genes that are
characteristic of brown and beige adipocytes, were not changed
(Table S2 in Supplementary Material). The significance of the
increases in MPZL2 and TNFRSF12A (Fn14, which is involved
in many cell processes, especially involving tissue injury) is
not known. Although KDT501 has anti-inflammatory effects
in vitro, KDT501 treatment did not significantly reduce TNFα,
IL12β, IL1β, or other inflammatory cytokines and immune cell
markers in the multiplex assay panel (Table S2 in Supplementary
Material). Finally, KDT501 did not change leptin gene expression
(Table S2 in Supplementary Material). The data for all of the genes
measured and the negative control values for each probe are in
Table S2 in Supplementary Material.

KDT501 Treatment Alters the Response
of Adipose Tissue to Cold Stimulation

KDT501 promotes weight loss in mice, and microarray results
from human adipocytes indicate that KDT501 stimulates thermogenic pathways in adipocytes (1), suggesting that KDT501
may promote WAT beiging. We have previously reported that a
30-min cold exposure stimulates beiging pathways in the adipose
tissue of lean humans (13). Therefore, before and after KDT501
treatment, we applied an ice pack to one side of the abdomen
for 30 min and 4 h later performed an adipose tissue biopsy,
as described in the Section “Materials and Methods.” We then
determined whether this cold stimulus changed gene expression
and whether KDT501 treatment altered the response to cold.
Before KDT501 treatment, the application of cold resulted in

FIGURE 1 | KDT501 induces total and high-molecular weight (HMW)
adiponectin secretion by adipose tissue explants from obese, insulin-resistant
subjects. Adipose tissue explants obtained before and after KDT501
treatment were incubated in Dulbecco’s modified Eagles’ medium (DMEM)
for 1 h at 37°C. (A) Total and (B) HMW adiponectin concentrations in the
DMEM were measured by ELISA and are expressed as the concentration/g
adipose/h. (C) Adiponectin gene expression was measured in the
corresponding adipose tissue biopsy with the Nanostring nCounter system
as described in the Section “Materials and Methods.” Data represent the
mean ± SEM (n = 9); data in all panels were analyzed by a paired, two-tailed
Student’s t-test (*P < 0.05).
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the significant repression of four unrelated genes, SCD, MMP14,
AGTR2, and IL18 (Table 2; data for all of the remaining genes
are in Table S3 in Supplementary Material).
After KDT501 treatment, a number of genes involved in
lipolysis and lipid catabolism were significantly induced by cold
(Table 3). These included PPARα, PGC1α, HSL, and ANGPTL4
(Table 3). Adipose triglyceride lipase (PNPLA2) and the coactivator of ATGL (CGI-58; ABHD5) showed a trend for induction
(Table 3). VEGF, which stimulates angiogenesis and beiging
(14), was also induced by icing (Table 3). Despite the induction

of lipolytic genes and PGC1α by cold, the 1.2-fold increase in
UCP1 was not significant (P = 0.34; Table S4 in Supplementary
Material). CCL1, a chemokine for eosinophils and Th2 T cells
(15, 16), was induced by cold after KDT501, which could be
important given the role of type 2 immunity (e.g., IL4 and IL-13)
in adipose beiging (17–20). Data for the remaining genes are in
Table S4 in Supplementary Material.
We identified genes that had a differential response to cold
before and after KDT501 treatment as described in methods
(Table S5 in Supplementary Material). This analysis identified
many of the same genes in Table 3 and some additional genes,
providing further insight. Before KDT501 treatment, the gene
expression of the thermogenic genes PGC1α, TMEM26, and
PPARα decreased slightly after cold stimulation; after KDT501
treatment, the expression of these genes increased (Figures 2A–C;
P < 0.05). VEGF, which induces beiging (14) and angiogenesis,
was also increased by cold after KDT501 treatment (Figure 2D;
P < 0.01). PAI-1 is regulated by TGFβ signaling, which inhibits
PGC1α and energy expenditure (21); PAI-1 was increased by cold
before KDT501, but did not increase after KDT 501 (Figure 2E;
P < 0.05). Overall, this suggests that KDT501 promotes the
expression of genes involved in lipolysis and fat catabolism in
response to cold. In addition, LPL increased in response to cold
after KDT501 treatment (Figure 2F).

TABLE 2 | Gene expression changed by cold before KDT501 treatment.
Genea

Pre cold

Post cold

Fold change

P

Post/pre
SCD
AGTR2
MMP14
IL18
FABP1
ACLY
ADRB2
CD163
THBS1
RBP4
CCL24
ADIPOQ

49,210 ± 12,496
7±1
548 ± 40
88 ± 10
10 ± 2
2,998 ± 624
72 ± 4
1,074 ± 84
968 ± 125
23,669 ± 1,752
90 ± 21
22,520 ± 1,671

44,454 ± 12,115
4±1
499 ± 34
74 ± 5
5±1
2,490 ± 444
66 ± 4
978 ± 71
1,163 ± 149
21,269 ± 2,232
75 ± 16
20,773 ± 1,250

0.90
0.66
0.91
0.83
0.51
0.83
0.92
0.91
1.20
0.90
0.83
0.92

0.008
0.013
0.030
0.034
0.055
0.061
0.066
0.069
0.079
0.091
0.094
0.100

KDT501 Enhances β-Adrenergic
Responses and Fatty Acid Oxidation
in Adipocytes

SCWAT was isolated before and after the cold stimulus before KDT501 treatment,
and gene expression determined with the Nanostring nCounter system as described
in the Section “Materials and Methods.”
The data are presented as means (nCounter Counts) ± SEM (n = 9; two-tailed,
paired Student’s t-test).
a

A potential explanation for the observation that KDT501 treatment enhances expression of thermogenic genes in response
to cold is that KDT501 sensitizes adipocytes to β-adrenergic
stimuli. To directly test this notion, fully differentiated mouse
primary brown adipocytes were pretreated with KDT501 or
rosiglitazone for 16 h, and their response to acute exposure to
NE was then monitored in real time by measuring the rate of
oxygen consumption in a Seahorse XFe instrument. As expected
for brown adipocytes, NE exposure stimulated oxygen consumption in vehicle (DMSO)-treated cells (Figure 3A). Pretreatment
with KDT501 robustly enhanced the response to NE (Figure 3A;
KDT501 P < 0.001; rosiglitazone P < 0.001). Pretreatment with
the positive control rosiglitazone had a similar effect. To expand
these observations and determine the extent to which KDT501
treatment could also induce a more oxidative state in white adipocytes, we treated fully differentiated 3T3-L1 adipocytes with
KDT501 for 48 h and determined the rate of fatty acid oxidation.
KDT501 treatment significantly increased the endogenous, or
basal (P < 0.001), and the maximal (P < 0.001) rate of exogenous
fatty acid oxidation (Figure 3B), suggesting that KDT501 treatment boosts mitochondrial function. Together, these data show
that KDT501 has direct effects on adipocytes, potentiating
β-adrenergic signaling and fatty acid oxidation.

TABLE 3 | Gene expression changed by cold after KDT501 treatment.
Genea

Pre cold

Post cold

Fold change

P

Post/pre
ANGPTL4
CCL1
BCL2
CSF2
LIPE
CEBPA
PPARA
VEGFA
PPARGC1A
DIO2
TEK
MMP9
ABHD5
FABP3
ITGAM
ANGPTL1
PNPLA2
LPL
FGF2

1,136 ± 174
7±1
456 ± 35
46 ± 4
225 ± 27
6,498 ± 568
179 ± 13
1,013 ± 86
48 ± 6
41 ± 9
263 ± 18
311 ± 117
537 ± 65
219 ± 61
291 ± 27
288 ± 27
6,664 ± 648
16,496 ± 2,584
1,019 ± 107

1,659 ± 163
12 ± 1
543 ± 45
53 ± 3
245 ± 26
7,549 ± 504
192 ± 12
1,150 ± 75
57 ± 9
24 ± 5
305 ± 24
210 ± 42
597 ± 74
148 ± 13
256 ± 19
222 ± 14
7,129 ± 490
18,240 ± 2,305
120 ± 91

1.46
1.59
1.19
1.17
1.09
1.16
1.07
1.13
1.19
0.58
1.16
0.68
1.11
0.68
0.88
0.77
1.07
1.11
1.10

0.001
0.003
0.004
0.009
0.018
0.019
0.030
0.035
0.038
0.049
0.051
0.052
0.054
0.065
0.068
0.075
0.078
0.090
0.092

Cold Treatment Stimulates Adiponectin
Secretion

SCWAT was isolated before and after the cold stimulus after KDT501 treatment,
and gene expression was determined with the Nanostring nCounter system as
described in the Section “Materials and Methods.”
The data are presented as means (nCounter Counts) ± SEM (n = 9; two-tailed,
paired Student’s t-test).
a
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The analysis of gene expression and in vitro assays above suggest
that KDT501 enhances β-adrenergic responses of adipocytes.
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FIGURE 2 | KDT501 treatment alters the subcutaneous white adipose tissue (SC WAT) transcriptional response to cold exposure. The Nanostring nCounter system
was used to measure gene expression in SC WAT of subjects treated before and after 1 month KDT501 treatment. A-F) Genes that had a different response to the
cold stimulus were identified as described in the Section “Materials and Methods.” Data represent the mean ± SEM (n = 9); data in all panels were analyzed by a
paired, two tailed Student’s t-test of the change in gene expression by cold before and after KDT501 treatment (*P < 0.05; **P < 0.01).

adiponectin (Figure 4B; P < 0.01) secretion from the SC WAT
explants before KDT501 treatment but did not affect adiponectin mRNA expression (Figure 4C). Cold also stimulated total
(Figure 4D; P < 0.05) and HMW adiponectin (Figure 4E; P < 0.01)
secretion from the SC WAT explants after KDT501 treatment but
did not affect adiponectin mRNA expression (Figure 4F).
Three proteins that promote adiponectin secretion have been
identified and could thus act posttranscriptionally to increase

Recently, a study by Komai and colleagues found that β- adrenergic signaling promotes adiponectin secretion (22). Since cold
stimulates the sympathetic nervous system and β-adrenergic
signaling, another potential mechanism for KDT501 stimulation
of adiponectin secretion could involve this pathway. To explore
this further, we measured adiponectin protein levels from the SC
WAT explants and observed that cold-stimulated adiponectin
secretion. Cold-stimulated total (Figure 4A; P < 0.01) and HMW
Frontiers in Endocrinology | www.frontiersin.org

6

September 2017 | Volume 8 | Article 255

Finlin et al.

KDT501 and Adipose Tissue Biology

DISCUSSION
There is a need to develop new therapies to combat obesity
and obesity-related disorders such as metabolic syndrome,
non-alcoholic fatty liver disease and steatohepatitis, and the
lipodystrophy of PCOS. We previously reported that KDT501
treatment of obese, insulin-resistant subjects for 28 days resulted
in an increase in plasma adiponectin and HMW adiponectin (2).
In this study, we found that SC WAT from these obese, nondiabetic human subjects is a target of KDT501 treatment and
investigated the mechanistic basis of its action. KDT501 stimulates total and HMW adiponectin protein secretion from SC
WAT explants, and this may be related to the ability of KDT501
to enhance mitochondrial function, which was revealed in
experiments using cultured adipocytes. Furthermore, additional analysis uncovered additional effects of KDT501 on
SC WAT. Multiplex analysis of gene expression revealed that
KDT501 enhanced expression of PGC1α, PPARα, and the beige
cell marker TMEM26 in response to cold. These findings are
consistent with the ability of KDT501 to enhance β-adrenergic
responses in primary brown adipocytes.
Adiponectin exists as a heterogeneous mix of multimers,
and plasma HMW adiponectin levels are negatively correlated
with various aspects of metabolic syndrome, including insulin
resistance (4). Following the transcription of the adiponectin
30 kDa monomer, considerable posttranslational processing
and assembly of the HMW multimer occurs, leaving multiple
possibilities for regulation. The inability of KDT501 to increase
transcription of the adiponectin gene indicates that KDT501
induces adiponectin secretion and multimerization posttranscriptionally. Multimerization of adiponectin into an HMW
form and its secretion are complex processes regulated by ER
stress, mitochondrial dysfunction, autophagy, and proteins
such as ERp44, Ero1-Lα, and DsbA-L (23–26). Our studies
demonstrating that KDT501 enhances fatty acid oxidation in
3T3-L1 adipocytes suggest that KDT501 has beneficial effects
on mitochondrial function. Mitochondrial function in adipose
tissue is impaired in obesity, and recent studies suggest that
impaired mitochondria function reduces adiponectin secretion (27–29). Therefore, the ability of KDT501 to increase
adiponectin secretion may be through its ability to enhance
mitochondrial function, as was revealed by our in vitro assays.
Another possible mechanism for the increase in adiponectin
secretion induced by KDT501 could be that KDT501 sensitizes adipocytes to β-adrenergic agonists, as was revealed by
our analysis of SC WAT gene expression and in vitro assays.
Recent studies have demonstrated that β-adrenergic signaling
pathways promote adiponectin secretion (22). We found that
cold stimulates adiponectin secretion in vivo, suggesting that
stimulation of β-adrenergic signaling increases adiponectin
secretion in vivo in obese subjects. Thus, the ability of KDT501
to enhance β-adrenergic signaling may also contribute to the
increased adiponectin secretion.
Pioglitazone has also been shown to induce adiponectin secretion by posttranscriptional mechanisms (30), and PPARγ agonists
are known for their powerful effects on increasing adiponectin
gene expression (31). However, data from this and other studies

FIGURE 3 | Adipocytes treated with KDT501 show a magnified response
to norepinephrine and increased fatty acid oxidation rate. (A) Mouse primary
brown adipocytes were treated for 16 h with DMSO (vehicle), KDT501
(10 µM), or rosiglitazone (2 µM). Oxygen consumption rate was measured
on a Seahorse XFe96 as described in the Section “Materials and Methods.”
(B) 3T3-L1 adipocytes were treated for 48 h with KDT501 (10 µM) or
rosiglitazone (2 µM), and the rate of basal (endogenous) and maximal
(exogenous palmitate added) fatty acid oxidation measured in real time
using the XFe96. Data represent four biological replicates. Error bars
indicate SD. **P < 0.01; ***P < 0.001 by one-way analysis of variance.

adiponectin secretion. Because of the increase in adiponectin
secretion without any change in mRNA level, we therefore
determined whether KDT501 or cold affected the expression of
these by real-time RT-PCR (primer sequences are in Table 4).
KDT501 treatment alone did not affect the mRNA expression of
any of these; however, all three were induced by cold. ERp44 was
induced by cold (Figure 5A; pre: P < 0.05; post: P < 0.001), and
KDT501 enhanced this effect (Figure 5A; P < 0.05). Ero-La was
induced by cold after KDT501 (Figure 5B; P < 0.05). DsbA-L was
induced by cold before and after KDT501 treatment (Figure 5C;
pre: P < 0.05; post: P < 0.01).

Summary

In summary, KDT501 treatment had a beneficial effect on SC
WAT of obese human research participants. KDT501 increased
adiponectin secretion by a posttranscriptional mechanism and
altered the transcriptional response of human adipose tissue
to cold stimulation, inducing the expression of many genes
involved in thermogenesis and lipolysis. Consistent with these
observations, the ability of KDT501 to enhance the response of
cultured adipocytes to β-adrenergic stimuli and increase mitochondrial function provides a potential mechanism of action.
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FIGURE 4 | Cold induces total and high-molecular weight (HMW) adiponectin secretion by adipose tissue explants of obese, insulin-resistant subjects.
Adipose tissue explants obtained before and after cold treatment (30 min) before and after KDT501 treatment were incubated in Dulbecco’s modified
Eagles’ medium (DMEM) for 4-h at 37°C. (A) Total and (B) HMW adiponectin secretion in the DMEM were measured by ELISA and are expressed as
the concentration/g adipose/h. (C) Adiponectin gene expression was measured in the corresponding adipose tissue biopsy with the Nanostring nCounter
system as described in the Section “Materials and Methods.” (D) Total and (E) HMW adiponectin secretion in the DMEM were measured by ELISA.
(F) Adiponectin gene expression was measured in the corresponding adipose tissue biopsy with the Nanostring nCounter system as described in the
Section “Materials and Methods.” Data represent the mean ± SEM (n = 9); data in all panels were analyzed by a paired, two tailed Student’s t-test
(*P < 0.05; **P < 0.01).

the mechanism by which KDT501 exerts changes in adiponectin
circulating levels. Our in vitro studies suggest that an improvement in mitochondrial function may be an important part of the
mechanism.
The data in this report are consistent with the increase in
plasma adiponectin in these research participants reported
earlier (2). Adipose tissue explants from these same subjects
secreted more total and HMW adiponectin after KDT501 treatment. Although adiponectin levels in plasma were increased,
our clinical study did not reveal changes in glucose metabolism
or insulin sensitivity (2). These subjects were only treated with
KDT501 for 28 days, and it is possible that longer treatment or

are not consistent with KDT501 directly stimulating PPARγ transcriptional activity. In vitro, KDT501 has been reported to have
pleotropic effects in adipocytes, including suppression of NFκB
signaling (1), and, perhaps, a weak PPARγ agonist effect. However,
in this study, we found no evidence of KDT501 PPARγ agonism
in humans. Direct PPARγ target genes such as adiponectin, LPL,
CD36, PNPLA2, and FABP4 were not induced by KDT501 treatment (Table S2 in Supplementary Material). Suppression of inflammation would also be predicted to promote adiponectin gene
expression, but numerous inflammatory cytokine and immune
cell markers were measured and not affected by KDT501. Thus,
it will be important to perform additional studies to determine
Frontiers in Endocrinology | www.frontiersin.org
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TABLE 4 | Real-time reverse transcriptase polymerase chain reaction primers.
Gene

Forward

Reverse

ACTB

GAG CAC AGA GCC
TCG CCT TT

CGC GGC GAT ATC
ATC ATC CAT

PP1A

CCC ACC GTG TTC
TTC GAC AT

GCT GTC TTT GGG
ACC TTG TCT

PP1B

AAG TCA CCG TCA
AGG TGT ATT TT

TGC TGT TTT TGT
AGC CAA ATC CT

TBP

CCC GAA ACG CCG
AAT ATA ATC C

AAT CAG TGC CGT
GGT TCG TG

TUBB

ACC AAC CTA CGG
GGA TCT GAA

TTG ACT GCC AAC
TTG CGG A

UBC 9

CTG GAA GAT GGT
CGT ACC CTG

GGT CTT GCC AGT
GAG TGT CT

ERp44

AGC CCA GAG ATA
CAG GAT AAG C

GTT GCC TGA TGT
AAT CTG CCA

ERO1L

GGC TGG GGA TTC
TTG TTT GG

AGT AAC CAC TAA
CCT GGC AGA

DsbA-L

TCT GGA AAA GAT
CGC AAC GC

GCC CAA AGG CTC
CGT ATC TG

higher blood levels of KDT501 are necessary to realize the full
beneficial effects of its ability to increase adiponectin.
Despite increasing the levels of adiponectin, which is an antiinflammatory adipokine, KDT501 had minimal effects on gene
expression in the absence of a cold stimulus. One explanation
for the lack of effect on gene expression is that the short-term
treatment did not cause weight loss (2), change % body fat, or
change resting energy expenditure. KDT501 treatment remodeled the transcriptional response of adipose tissue to cold and
increased expression of genes involved in lipolysis and thermogenesis. We have recently reported that lean, healthy subjects
respond to the same cold stimulus used in this study with a
significant increase in expression of PGC1α and TMEM26 at
the RNA level (13). The induction of PGC1α and TMEM26 in
response to cold after KDT501 treatment seen here was lower
than that measured in the lean subjects of our earlier study (13).
Nonetheless, this indicates a beneficial effect of KDT501 on SC
WAT, for PGC1α expression in white adipose tissue promotes
insulin sensitivity (32). It is also important to note that this
study was done entirely in the summer. We have previously
documented seasonal effects on thermogenic gene expression
in humans. Baseline expression of thermogenic genes in lean
subjects is lower in the summer, and we saw greater changes
in response to a cold stimulus in the summer (13). These findings indicate reduced β-adrenergic signaling in humans in the
summer, which may explain why greater changes in PGC1α
and TMEM26 expression after KDT501 treatment were not
seen in the present obese subjects. KDT501 robustly enhanced
NE-stimulated cellular respiration in primary brown adipocytes, suggesting a mechanism for the increase in PGC1α and
TMEM26 expression upon cold exposure in vivo: KDT501 sensitizes adipose tissue to β-adrenergic signaling. This mechanism
may contribute to the weight loss observed in KDT501-treated
mice, studies that were performed at room temperature, below
thermoneutrality for mice (1).

Frontiers in Endocrinology | www.frontiersin.org

FIGURE 5 | Effect of KDT501 and cold on the expression of genes that
regulate adiponectin secretion and multimerization. (A–C) Gene expression
was measured by real-time reverse transcriptase polymerase chain reaction
as described in the Section “Materials and Methods.” Data represent the
mean ± SEM (n = 9); data in all panels were analyzed by a repeated
measures analysis of variance (*P < 0.05; **P < 0.01; ***P < 0.001).
The data in all panels were also analyzed by a paired, two tailed Student’s
t-test of the change in gene expression by cold before and after KDT501
treatment (ERp44: *P < 0.05).

ANGPTL4 expression was highly induced by cold after
KDT501 treatment. Since ANGPTL4 can be induced by free fatty
acids acting through PPARδ (33), this may be a sign of increased
lipolysis. Interestingly, ANGPTL4 itself contributes to lipolysis
by stimulating adipocyte cAMP levels (34, 35). Recent studies
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in mice indicate that ANGPTL4 is induced in WAT in response
to cold to inhibit LPL and thus favor the delivery of lipids to BAT
(36). KDT501 appears to restore this tissue-specific regulation of
ANGPTL4 by cold in obese subjects. PGC1α was also induced
by cold after KDT501 treatment along with a number of other
genes involved in lipid catabolism, including PPARα. Notably,
UCP1 expression was not induced. This finding may be ascribed
to the fact that cold-stimulated induction of UCP1 is blunted
by chronic inflammation in obese subjects (13), and KDT501
did not reduce SC WAT inflammation, as evidenced by a lack
of change in expression of multiple inflammatory genes. It is
also possible that the timing of the biopsies, 4 h after the 30 min
cold stimulus, may not have been suited to capture cold-induced
changes in UCP1 mRNA.
Taken together, the results of this initial study reveal that
SC WAT is a physiologic target of KDT501. KDT501 acts by
at least two mechanisms. It promotes adiponectin secretion
by a posttranscriptional mechanism that may be related to
its ability to improve mitochondrial function. KDT501 also
enhances thermogenic gene expression upon cold exposure,
a property that may be due to its ability to sensitize cultured
adipocytes to β-adrenergic stimuli. Longer exposure to
KDT501 may have beneficial effects on adipose tissue dysfunction implicated in conditions such as T2D, PCOS, and NASH
in humans.
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